Highlight 4 in lung cancer
Dr. Mariana Brandao from the Institut Jules Bordet in Brussels provided insightful commentary on three interesting presentations from the oral abstract session on metastatic non small cell lung cancer.
The phase 3 KEYNOTE-789 study was discussed in great detail, with a final analysis presented on the comparison between the combination of pemetrexed and platinum-based chemotherapy, with or without pembrolizumab, as a subsequent therapy for patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC.
Additionally, the phase 1b TROPION-LungO2 study was discussed, which reported on the safety and tolerability of the combination of datopotumab deruxtecan and pembrolizumab, with or without platinum chemotherapy.
One particularly interesting topic introduced by Dr. Brandao was Tumor Treating Field therapy, a new way of treating lung cancer patients. This therapy was compared to the standard of care in mNSCLC following platinum failure in the LUNAR study.
With the educational support of:
